A trial to investigate the efficacy and feasibility of treatment with dose adjusted EPOCH-R (DA-EPOCH-R), adapted to risk profile in patients with newly diagnosed Burkitt lymphoma.
Recruiting
- Conditions
- Burkitt lymphoma, Burkitt Lymfoom
- Registration Number
- NL-OMON26111
- Lead Sponsor
- VU University Medical Center Amsterdam
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 22
Inclusion Criteria
1. First diagnosis of Burkitt lymphoma, histological confirmed according to the WHO classification 2008;
2. Age ≥ 18 years;
Exclusion Criteria
1. All histopathological diagnoses other than BL according to the WHO classification 2008, irrespective of the presence of MYC rearrangement;
2. Inadequate renal function or creatinine clearance < 50 ml/min unless lymphoma related;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. 2 years overall survival (OS; time from registration. Patients still alive or lost to follow up are censored at the date they were last known to be alive) and progression free survival (PFS; i.e. time from registration to progression or death from any cause, whichever comes first);<br /><br>2. Number of cycles of the DA-EPOCH-R scheme completed on an out-patient –clinic basis.
- Secondary Outcome Measures
Name Time Method egative predictive value of low dose PET/CT scan after 2 cycles of DA-EPOCH-R on OS and PFS.